Hernandezine

CAS No. 6681-13-6

Hernandezine( —— )

Catalog No. M29163 CAS No. 6681-13-6

Hernandezine is an activator of AMPK activator and a selective reversing agent for ABCB1-mediated MDR in cancer cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 244 In Stock
10MG 392 In Stock
25MG 639 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Hernandezine
  • Note
    Research use only, not for human use.
  • Brief Description
    Hernandezine is an activator of AMPK activator and a selective reversing agent for ABCB1-mediated MDR in cancer cells.
  • Description
    Hernandezine is an activator of AMPK activator and a selective reversing agent for ABCB1-mediated MDR in cancer cells.(In Vitro):Hernandezine inhibits LPS-induced TNF-α expression/production in human macrophage cell lines (THP-1 and U93). Hernandezine inhibits the transport function of ABCB1, and enhances drug-induced apoptosis in cancer cells. Hernandezine significantly resensitizes ABCB1-overexpressing cancer cells to multiple chemotherapeutic drugs at nontoxic, nanomolar concentrations.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    TNF
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    6681-13-6
  • Formula Weight
    652.788
  • Molecular Formula
    C39H44N2O7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COc1ccc2C[C@@H]3N(C)CCc4c(OC)c(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Dalbergin

    Dalbergin exhibits similar bone conserving effect against bone-loss as estradiol treatment, it as a therapeutic candidate against postmenopausal osteoporosis.

  • Pomalidomide

    A potent inhibitor of TNF-α production; inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.

  • Utomilumab

    Utomilumab (PF 05082566) is a humanized IgG2 antibody that targets the T-cell co-stimulatory receptor 4-1BB/CD137 and acts as a 4-1BB/CD137 agonist.